Overall, these data indicate that UCB modulates Th17 cell metabolic status, mainly by impacting glycolysis and through the downregulation of glycolysis-associated genes like PGK1 and ALDOA. These changes are prominent in cells obtained from healthy individuals but not in those obtained from Crohn’s disease patients. This evidence concerns the gene ALDOA and Crohn disease.